Baricitinib (Olumiant; Eli Lilly) has demonstrated significant efficacy and a favorable safety profile in adults with severe alopecia areata, according to a new real-world prospective study. Over 50% of patients experienced substantial hair regrowth within one year of treatment, bridging a critical gap between clinical trial data and routine dermatology practice, where long-standing disease, prior treatment failures, and comorbidities are common. The findings were published in the Journal of Dermatologic Treatment.
The study followed 48 adults with severe alopecia areata for 12 months to evaluate the effectiveness, safety, and predictors of response to baricitinib, a Janus kinase (JAK) inhibitor approved for this condition. The primary endpoint was achieving a Severity of Alopecia Tool (SALT) score below 20%, sustained across at least two assessments separated by 12 weeks during the first year of therapy.
Participants had a mean age of 37 years, with two-thirds being female. The cohort had a high disease burden, with an average disease duration of over 10 years and baseline scalp hair loss categorized as severe (mean SALT score of 66.9). About one-third of patients had alopecia totalis or universalis, and 60% had eyebrow or eyelash involvement. Many also presented with comorbid autoimmune or inflammatory conditions, including hypothyroidism, atopic dermatitis, and psoriasis.
Patients had previously undergone multiple treatments, including topical and systemic corticosteroids, intralesional corticosteroids, minoxidil, methotrexate, and prior JAK inhibition with tofacitinib, highlighting the refractory nature of disease in this population. Most participants (87.5%) initiated baricitinib at the recommended 4 mg/day dose, with some adjustments made based on adverse events or clinical response.
Over 12 months, mean SALT scores dropped significantly from 67% at baseline to 22% at month 12 (P < .001), with the most pronounced improvements seen in the first six months. By months 9 and 12, 58.3% of patients achieved the primary endpoint (SALT < 20%), while 37.5% reached complete response (SALT < 10%). Eyebrow and eyelash regrowth also improved significantly.
Response patterns varied, with 29.5% classified as early responders, 25% as gradual responders, 9.1% as late responders, and 36.4% as nonresponders. Younger age, shorter disease duration, lower baseline SALT scores, and higher baseline erythrocyte sedimentation rate (ESR) were associated with higher complete response rates. Multivariate analysis identified shorter disease duration and lower baseline SALT scores as independent predictors of complete response.
Baricitinib was generally well-tolerated. Acne was the most common adverse event (17.6%), followed by dyslipidemia (7.8%). Other adverse effects, including asthenia, elevated liver enzymes, and weight gain, occurred in fewer than 4% of patients. Notably, over half of participants reported no adverse events, and no serious adverse events were observed.
The study reinforces baricitinib as an effective and safe treatment option for severe alopecia areata, especially when started early and in patients with less severe baseline disease. Researchers emphasized the importance of timely intervention and careful patient selection to optimize clinical outcomes. They also called for larger, multicenter prospective studies with longer follow-up to better understand long-term benefits, particularly for patients with partial responses during the first year.
